Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
ansuvimab
DRUG
2 trials
Sponsors
ANRS, Emerging Infectious Diseases
, Ridgeback Biotherapeutics, LP
Conditions
Ebola Virus Disease
Phase 2
Prophylaxis Vaccine Antibodies Ebola
NCT04822376
ANRS, Emerging Infectious Diseases
Ebola Virus Disease
Start: 2021-10-17
End: 2022-04-30
Target: 250
Updated: 2021-10-15
Unknown Phase
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
NCT05067166
Ridgeback Biotherapeutics, LP
Ebola Virus Disease
Updated: 2024-12-17